Suppr超能文献

慢性阻塞性肺疾病重症 2019 冠状病毒病患者的临床特征。

Clinical characteristics of severe coronavirus disease 2019 patients with chronic obstructive pulmonary disease.

机构信息

Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha 410008, China.

出版信息

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022 Dec 28;47(12):1695-1703. doi: 10.11817/j.issn.1672-7347.2022.210596.

Abstract

OBJECTIVES

Coronavirus disease 2019 (COVID-19) in elderly and patients with chronic respiratory diseases (COPD) had a poor prognosis. COPD is one of the most common chronic respiratory diseases. We explore the epidemiological characteristics of patients with severe COVID-19 with COPD patients in order to provide medical evidence for the prevention and treatment of severe COVID-19.

METHODS

We retrospectively analyzed the clinical baseline characteristics, treatment strategies, disease progression and prognosis of 557 severe COVID-19 patients admitted to the West Court of Union Hospital of Huazhong University of Science and Technology from January 29, 2020 to April 8, 2020.

RESULTS

A total of 465 patients with severe COVID-19 were enrolled in the study, including 248 (53.3%) males and 217 (46.7%) females. The median age of severe COVID-19 patients was 62.0 years, and 53 patients were complicated with COPD. Common symptoms at the onset included fever (78.5%), dry cough (67.1%), shortness of breath (47.3%) and fatigue (40.9%). Compared with non-COPD patients, patients with COPD had significantly lower levels of SpO2 in admission (90.0% vs 92.0%, P=0.014). In terms of laboratory examinations, patients with COPD had higher levels of C-reactive protein, interleukin-6, procalcitonin, total bilirubin, blood urea nitrogen, serum creatinine, lipoprotein (a), high-sensitivity troponin I, and D-dimer, while had lower levels of platelet counts, albumin and apolipoprotein AI. Severe COVID-19 patients with COPD had higher Sequential Organ Failure Assessment scores [3.0(2.0, 3.0) vs 2.0(2.0, 3.0), P=0.038] and CURB-65 score [1.0(1.0, 2.0) vs1.0(0.0, 1.0), P<0.001], and a higher proportion of progressing to critical illness (28.3% vs 10.0%, P<0.001) with more complications [e.g. septic shock (15.1% vs 6.1%, P=0.034)], had higher incidence rates of antibiotic therapies (90.6% vs 77.2%, P=0.025), non-invasive (11.3% vs 1.7%, P<0.001) and invasive mechanical ventilation (17.0% vs 8.3%, P=0.039), ICU admission (17.0% vs 7.5%, P=0.021) and death (15.1% vs 6.1%, P=0.016). Cox proportion hazard model was carried out, and the results showed that comorbid COPD was an independent risk factor for severe COVID-19 patients progressing to critical type, after adjusting for age and gender [adjusted hazard ratio (AHR)=2.38(1.30-4.37), P=0.005] and additionally adjusting for chronic kidney diseases, hypertension, coronary heart disease [AHR=2.63(1.45-4.77), P<0.001], or additionally adjusting for some statistically significant laboratory findings [AHR=2.10(1.13-3.89), P=0.018].

CONCLUSIONS

Severe COVID-19 patients with COPD have higher levels of disease severity, proportion of progression to critical illness and mortality rate. Individualized treatment strategies should be adopted to improve the prognosis of severe COVID-19 patients.

摘要

目的

新冠肺炎(COVID-19)在老年患者和慢性呼吸系统疾病(COPD)患者中预后较差。COPD 是最常见的慢性呼吸系统疾病之一。我们探讨了严重 COVID-19 患者中合并 COPD 患者的流行病学特征,为严重 COVID-19 的防治提供医学证据。

方法

我们回顾性分析了 2020 年 1 月 29 日至 2020 年 4 月 8 日期间华中科技大学同济医学院附属协和医院西院收治的 557 例严重 COVID-19 患者的临床基线特征、治疗策略、疾病进展和预后。

结果

共纳入 465 例严重 COVID-19 患者,其中男性 248 例(53.3%),女性 217 例(46.7%)。严重 COVID-19 患者的中位年龄为 62.0 岁,53 例合并 COPD。常见的首发症状包括发热(78.5%)、干咳(67.1%)、呼吸急促(47.3%)和乏力(40.9%)。与非 COPD 患者相比,COPD 患者入院时 SpO2 水平明显较低(90.0%比 92.0%,P=0.014)。在实验室检查方面,COPD 患者的 C 反应蛋白、白细胞介素-6、降钙素原、总胆红素、血尿素氮、血肌酐、脂蛋白(a)、高敏肌钙蛋白 I 和 D-二聚体水平较高,血小板计数、白蛋白和载脂蛋白 AI 水平较低。合并 COPD 的严重 COVID-19 患者序贯器官衰竭评估(SOFA)评分较高[3.0(2.0,3.0)比 2.0(2.0,3.0),P=0.038]和 CURB-65 评分较高[1.0(1.0,2.0)比 1.0(0.0,1.0),P<0.001],进展为危重症的比例较高(28.3%比 10.0%,P<0.001),并发症较多[如感染性休克(15.1%比 6.1%,P=0.034)],抗生素治疗比例较高(90.6%比 77.2%,P=0.025),无创(11.3%比 1.7%,P<0.001)和有创机械通气(17.0%比 8.3%,P=0.039)、重症监护病房(ICU)入住率(17.0%比 7.5%,P=0.021)和死亡率(15.1%比 6.1%,P=0.016)较高。进行 Cox 比例风险模型分析,结果显示,在调整年龄和性别后,合并 COPD 是严重 COVID-19 患者进展为危重症的独立危险因素[调整后危险比(AHR)=2.38(1.30-4.37),P=0.005],并且在进一步调整慢性肾脏病、高血压、冠心病时[AHR=2.63(1.45-4.77),P<0.001],或进一步调整一些有统计学意义的实验室发现时[AHR=2.10(1.13-3.89),P=0.018]。

结论

合并 COPD 的严重 COVID-19 患者疾病严重程度更高,进展为危重症和死亡率更高。应采用个体化治疗策略,以改善严重 COVID-19 患者的预后。

相似文献

本文引用的文献

3
COVID-19 Transmission, Current Treatment, and Future Therapeutic Strategies.COVID-19 的传播、当前治疗方法和未来治疗策略。
Mol Pharm. 2021 Mar 1;18(3):754-771. doi: 10.1021/acs.molpharmaceut.0c00608. Epub 2021 Jan 19.
4
COVID-19 vaccines: The status and perspectives in delivery points of view.COVID-19 疫苗:交付观点中的现状和展望。
Adv Drug Deliv Rev. 2021 Mar;170:1-25. doi: 10.1016/j.addr.2020.12.011. Epub 2020 Dec 24.
6
Features of severe COVID-19: A systematic review and meta-analysis.严重 COVID-19 的特征:系统评价和荟萃分析。
Eur J Clin Invest. 2020 Oct;50(10):e13378. doi: 10.1111/eci.13378. Epub 2020 Aug 29.
10
Immune Response, Inflammation, and the Clinical Spectrum of COVID-19.免疫反应、炎症与 COVID-19 的临床谱。
Front Immunol. 2020 Jun 16;11:1441. doi: 10.3389/fimmu.2020.01441. eCollection 2020.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验